Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 3.01 · 8-K

Curis, Inc.

CRISNASDAQEQUITYCurrent

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 2, 2026, Curis, Inc. (the “Company”) received a letter (the “Delist Determination Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for th…

Filed Nov 6, 2026Accepted Nov 6, 2026, 4:30 PM ESTCIK 1108205Accession 0001104659-26-123906
Share

Company context

We are a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase, or IRAK4 and FMS-like tyrosine kinase 3 or FLT3. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma, or PCNSL, in combination with ibrutinib, a Bruton Tyrosine Kinase inhibitor or BTK inhibitor and in our recently initiated TakeAim CLL study, a Phase 2 combination study of emavusertib in chronic lymphocytic leukemia, or CLL, with zanubrutinib, a BTK inhibitor. Our monotherapy and combination studies of emavusertib in AML are substantially complete. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration, or FDA, for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. We, through our 2015 collaboration with Aurigene Discovery Technologies Limited, or Aurigene, have the exclusive license to emavusertib (CA-4948).

Current securities

Recent company filings

  1. S-8 POS filingNov 13, 2026
  2. S-8 POS filingNov 13, 2026
  3. S-8 POS filingNov 13, 2026
  4. S-8 POS filingNov 13, 2026
  5. S-8 POS filingNov 13, 2026

Registered securities in this filing

Curis, Inc. · 8-K · Filed 2026-11-06

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, Par Value $0.01 per share

Symbol
CRIS
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: AsOf2026-11-02

Dimensions: Not supplied

Accession 000110465926123906 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 3.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 3.01Item 3.01 - Notice of Delisting
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 2, 2026, Curis, Inc. (the “Company”) received a letter (the “Delist Determination Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). As the Company effected a 1-for-20 reverse stock split on July 6, 2026, the Company is not eligible for any compliance period specified in Rule 5810(c)(3)(A) due to the fact that, pursuant to Listing Rule 5810(c)(3)(A)(iv), the Company has effected a reverse stock split over the prior one-year period or has effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one. Additionally, following the Nasdaq Hearings Panel’s (the “Panel”) decision, dated July 24, 2026, the Company is subject to a Discretionary Panel Monitor under Listing Rule 5815(d)(4)(A) for a period of one year (the “Panel Monitor”). The Company intends to make a timely request for a new hearing with the initial Panel or a newly convened Panel if the initial Panel is unavailable, which will stay any further delisting actions. However, there can be no assurance that such appeal will be successful or that the Company will remain listed on Nasdaq. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including, without limitation, any statements with respect to the Company’s intent to appeal the Delist Determination Letter, ability to receive a hearing with any Panel or its ability to suspend or delay its delisting from Nasdaq. Forward-looking statements may contain the words "believes," "expects," "anticipates," "plans," "intends," "seeks," "estimates," "assumes," "predicts," "projects," "targets," "will," "may," "would," "could," "should," "continue," "potential," "focus," "strategy," "mission," or similar expressions. Actual results may differ materially from those indicated by such forward-looking statements. Important factors that could cause actual results to differ materially from those in these forward-looking statements include, but are not limited to, risks referenced in Item 1A, “Risk Factors” of Part I of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as such factors may be updated from time to time in other filings that the Company periodically makes with the SEC including, but not limited to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026. In addition, any forward-looking statements represent the views of the Company only as of the date of this Current Report on Form 8-K and should not be relied upon as representing the Company’s views as of any subsequent date. The Company disclaims any intention or obligation to update any of the forward-looking statements after the date of this Current Report on Form 8-K whether as a result of new information, future events or otherwise, except as may be required by law.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.